pylori-induced VEGF production of gastric epithelial cells. “
“Helicobacter pylori (H. pylori) infection is a major risk factor for gastric cancer (GC); however, only a minority of infected individuals develops GC. We aim to assess the association between serostatus of antibody against H. pylori flagellin A (FlaA) and risk of GC and to evaluate the value of serum FlaA antibody as a novel screening biomarker for GC risk. A hospital-based case–control study including 232 cases and 264 controls was conducted. Logistic regression was adopted to analyze the association
between the serostatus of FlaA antibody and risk of GC. Serum FlaA antibody was measured by an enzyme-linked immunosorbent assay (ELISA). Receiver Everolimus operating characteristic (ROC) curve was used to evaluate the screening efficacy and to identify a cutoff point of serum FlaA antibody level. Helicobacter pylori infection was associated with an increased risk of GC (p = .007). A positive association between serum FlaA antibody and GC risk was observed in overall subjects and H. pylori-positive subjects (OR [95% CI]: 6.8 [4.3–10.7] and 6.9 [3.6–13.4], respectively; p < .001). The seropositivity of FlaA antibody was strongly related to GC risk in a dose-dependent manner (p for trend < .001). The optimal cutoff value (OD) was 0.1403, providing a sensitivity of 74.1% and a specificity of 64.4%. The area under the ROC curve (AUC)
was 0.74 in overall subjects and 0.73 in H. pylori-positive subjects, respectively. FlaA was an independent risk factor
click here for H. pylori-related GC. Serum FlaA antibody may serve as a novel noninvasive biomarker for early detection of GC. Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer-related death worldwide [1-3]. Although it has become a relatively rare cancer in North America and most parts of Africa, GC remains prevalent in Eastern Asia, Eastern Europe, and South America [3, 4]. There is a big difference in the prognosis between the early stage and advanced stage of GC. The 5-year survival Tolmetin rate for patients with early-stage tumor is 80% [5, 6]. However, most of patients are diagnosed at an advanced stage, with a 5-year survival rate of 10% [6, 7]. In the Western world, for example, more than 80% of patients have advanced GC at diagnosis with a poor prognosis . Since the discovery of Helicobacter pylori (H. pylori) in 1983, intensive research has led to the conclusion that infection with this bacterium is a major cause for GC [9-12]. Epidemiological studies have shown that H. pylori infection is found in more than 70% of patients with GC, and those infected with H. pylori conferred up to a 21-fold increased risk of developing noncardia GC compared with the general population [13-15]. Although the virus infection is a high-risk factor for GC, only a small portion of individuals colonized with H. pylori ever develop GC, suggesting that differences in virulence of H.